Fig. 3

Sp1 promotes SH3GLB1 expression. A Genetic expression of SH3GLB1 and Sp1 from the GBM dataset of the CGGA database is shown in scatter plots with correlation assessment. B Schematic graph suggesting the potential Sp1 binding site on the SH3GLB1 promoter. Enhanced binding of Sp1 to the SH3GLB1 promoter is shown by chromatin immunoprecipitation assay in the resistant cells. C Western blot analysis showing enhanced Sp1 and SH3GLB1 expression in the resistant cells. D Western blot analysis showing reduced SH3GLB1 expression in the resistant cells with siSp1. E Western blot analysis showing that mithramycin A (MA) alleviated the TMZ-induced enhancement of Sp1 and SH3GLB1. F Sorted CD133⁺ and CD133⁻ subsets from patient-derived primary GBM cells. The former exhibit higher Sp1, LC3B-II and lower p62 in the Western blot analysis. N = 3 in each group, *p < 0.05